免费文献传递   相关文献

Experimental study of Tangshen formulain improved lipid metabolism and phenotypic switch of macrophage in db/db mice

糖肾方改善db/db小鼠脂代谢紊乱与巨噬细胞活化分型的实验研究



全 文 :2016
y

z À
41
ÁÀ

}
Vol41,No.9 May,2016
·
`;
·

gh)(
] 20151109

ijkR
] 
«_`abtcSef
(81130066);
«_«(2011DFA31860);
ƒgúbüÀÁef
(Z151100003815015)

le?m
] 
rj

mno

pqrst
,Tel:(010)64227163,Email:lp8675@163com
cdúef
db/db
:gRP×hiÖjkl’
·_¡mœno‰Š
çÖ
1,2,
]èé
2,
]ê‹
2,
ëì
2,
rj
1,2,3
(1.
ü«tbt‚

ƒg„Yt‚ mnr‚

ƒg
100730;
2.
üOPQÞRtmnˆ h‡h˗

ƒg
100029;
3.
STUVWƒgúg”•–—

ƒg
100029)

pq
] 
š€

RP×hi‚âãPרq

pqž|Õ!R÷™
(NAFLD)
ûDXœ_¾G›S

qB=ïy@2

Ò«
ÓI¾ŒB§ç/œ½!¨q…[

ډŠÑ_~ŠcdúÏ
C57BLKS/Jdb/db(db/db)
:gRP×hiÖjkl’·_¡
mœ‡¯fˆ
。8
³ƒ!Mm!c¦qš€
db/db
:gÖ¦>¥mq
db/m
:g

Îf¡Ó‘ƒÏ–Ò
(db/m)、
xmÒ
(db/db)、
cdúC,Ò
(db/db+TSF),
JK‚˜
12
ÿ‘䃨

3Ò¸ëõX¯

äò

ßí¶º™´Rƒ°E

c£Ò
¸_û¶º™´jkl’·_¡mëj¨
CD68,F4/80
œŸ N_

Å_`†
PCR
û¶ºöíR÷Ò¸jkl’·_ëj¨
Mrc1,Arg1,TNFαÉmRNAŸ 。‰ŠmÝ֑ƒÏ–ÒâŸ,xmÒ:g™Ò¸R…°E@Z,TSF’õÿR…°EV¹*
F
;db/db
:g™´Ò¸
CD68
#
F4/80
œŸ @2
,TSF
’õÿ?V¹Mˆ‚Ÿ Jþ

Ù+

֑ƒÏ–ÒâŸ
,db/db
:g
öíR÷Ò¸jkl’·_ëj¨
Mrc1,Arg1
#
TNFαmRNAŸ @2,TSF’õÿTNFαV¹ST,vMrc1,Arg1=V¹
E

᠟¡$,cdú?*
db/db
:g™´R÷N

eftREƒ

‚fˆ?—Ö‚»Ájkl’·_Bã


rst
] 
cdú

ž|Õ!R÷™

™´R÷N

jkl’·_
ExperimentalstudyofTangshenformulainimprovedlipidmetabolismand
phenotypicswitchofmacrophageindb/dbmice
KONGQin1,2,ZHANGBingxuan2,ZHANGHaojun2,YANMeihua2,LIPing1,2,3
(1.GraduateSchoolofPekingUnionMedicalColege,ChineseAcademyofMedicalSciences&Peking
UnionMedicalColege,Beijing100730,China;
2.DepartmentofPharmacology,InstituteofClinicalMedicalSciences,ChinaJapanFriendshipHospital,Beijing100029,China;
3.BeijingKeyLabforImmuneMediatedInflammatoryDiseases,Beijing100029,China)
[Abstract] Obesityanditsassociatedmetabolicdisorders,includingnonalcoholicfatyliverdisease(NAFLD),havebecomemajor
chronicdiseasesthreateningpublichealthNAFLDisachronicliverdisorderthatisstronglyassociatedwithtype2diabetesandobesi
tyInthisstudy,weinvestigatedtheefectsandmechanismofTangshenformula(TSF)onhepaticdyslipidemiaandphenotypicswitch
ofmacrophageindb/dbmiceEightweekoldmaleC57BLKS/Jdb/mcontrolanddb/dbmiceweredividedinto3groups(namelydb/
m,db/db,db/db+TSF),andfedwithTSFordistiledwaterfor12weeksItwasfoundthataftertreatmentwithTSF,thetriglycer
idesaccumulationindb/dbmicewasdecreasedonthebasisofoilredOstainingwithcryosectionsoflivertissuesAndproteinexpres
sionsofmacrophageactivationmarkersCD68andF4/80weredecreasedaccordingtoimmunohistochemicalanalysisofhepaticsections
·3961·
2016
y

z À
41
ÁÀ

}
Vol41,No.9 May,2016
ThemRNAlevelofTNFα(M1marker)wassignificantlydecreasedbyTSFindb/dbmice,butwithnosignificantdiferenceinMrc1
andArg1(M2marker)Accordingtotheresults,TSFatenuatedhepaticsteatosisandrelieveddyslipidemia,itsmechanismmaybe
corelatedwiththeregulationofmacrophageactivationandphenotypicswitch
[Keywords] Tangshenformula;nonalcoholicfatyliverdisease(NAFLD);hepaticsteatosis;macrophageactivation
doi:10.4268/cjcmm20160920
  
ž|Õ!R÷™q
(nonalcoholicfatyliverdis
ease,NAFLD)
û[§ÂŠäLþÓќR…¤™
´Ò¸$Eƒ¡EÓq}eNœ¨q

œƒ|#‚
¤Ò¡\œ™¥¦›S
),
û.Ӄ„œ[§½!
™´¨q

ååo%qªmÓ
15% ~30%[1]。
‚
m©mŒpqR¹!R÷™

R÷!™ÿ

™†_#
™¥

Cßé

B‰ŠVĔuBÆ$c¦q

š
€tREƒ•$
NAFLD
œqªV¹@2

m
Ó
35%~80%[1]。
ÆKååÏ
NAFLD
œXôuä


v
NAFLD
q›#mqfˆˆÓf-

åå
[bêw¡â

ãy‰ŠŸ¡
NAFLD
œm©mŒ
֚€

„¸S…,

ÿ§jkl’·_BÏ]d
œ>ô

B‰ŠmÝ

jkl’œ·_¡m¤š€
—˜œÒ¸ÿ§#„¸S…,$mEÏ_‡¯

‚Ïê
NAFLD
œm©mŒBÏV¹œ»Á‡¯

‚
™·ú(Œ>
(activated,M1)
Ö÷ø!
(alterna
tivelyactivated,M2)
™·ú(ÂÖِ“œm©m
Œ
[2]。
cdúû²þÛܙ¶¼M$AŒo•¶
fuáœ&‰¯ú

ÂB‰ŠŸ¡$,fúcdú
†¨?V¹*c¦qdqwg™d¥¦qT«t
…ŠäLþ#u+C˜Jþ
[3]。
õ‰Š@Ê¯
NAFLD
xm
db/db
:g‰ŠcdúςR…P×
œØÙq~jkl’¥¦¡m¤
NAFLD
$œ‡
¯

ÓcdúS[:®¯ö¯2ð&ñò

1 
Ü#Öúû
11 
òíÖß´
 TRIzol
òí
(Invitrogen,
°%
);
õlmòíä
(ThermoFisher,
°%
);UltraSYBR
Mixture(
/Ó¹kDE

$%
);
äò

ß>
(Sigma,
°%
);CD68

[Abcam(1∶400),
°%
];F4/80
,
ó
[Abcam(1∶200),
°%
];
_Vî}
(Olympus
BX43
m_Vî}


);ABI7500
Å_`†
PCR
ß
(ABI,
°%
)。
12 
Ĭ
 
Mm!

mc¦qš€
C57BLKS/J
db/db
:g

ÂSQX
db/db
:g
),
ƒ!
,8
³

ó
(35±5)g;
¦ZW`;
C57BLKS/Jdb/+
‘ƒ
:g

ÂSQX
db/m
:g
),
ó
(20±2)g,
Âf
ƒ¨§M23wnoƒ¨$S

ƒ¨©-‡?v
<
SCXK(
3
)20110001。
ºB:g›˜ê${ú
Aþ
SPF
Jnoƒ¨ðšîMÄ

﯇?v<
SYXK(
3
)20100011。
^
(23±3)℃,
âÏ$^
(55±15)%,

12h
¡Gb¥

MwƒJ#‹Å

d@›#›‚

õ}noºB͇ÆIJé–no
ƒ¨ }âãª`‹n

13 
Yò,¨
 
cdúÖú†¨

*ð”*,È
BCDEˆí
),
©<
1206346,
ªJ
8g/´ 。
Ò«

(.

©F

w(
、¸
‡ˆ

klt

Lk

‰w

ö$
,

noƒ¨§ù?ö!‚˜



Xq‹n•
¶ÞÊý

Îf¡ÒOP„Ÿ
1。
noƒ¨êÀ
10
rmÕC,

|{

}

|X

JKC,
12


cdúí†Âüå}®¯‰Šqé–ëì
ƒ¨í†Ít
[4]。
Ÿ
1 
noƒ¨¡ÒC,
(n=9)
Table1 Subgroupingandadministration(n=9)
Ò^ ’õZ¼ í†
‘ƒÏ–
(db/m)
|}J óE¦cdúÒ
xm
(db/db)
|}J óE¦cdúÒ
cdú
(db/db+TSF)
cdú 24g·kg-1·d-1
14 
ëõw³
 
•Å
12h,
Û8Š3t

vS²³

,-20℃
íµX¯

wMƒ©_߶ºtœu
+C˜
(totalcholesterol,TC)
#ŠäLþ
(triglycer
ide,TG)。
noƒ¨êÀ
22
‘ä

²³™´#Ë
SöíR÷Ò¸

»¼”3J¡

X

d31¡
4%
Z}ӣ$C`
1h,
3Ö½ù
30%
ÍcÎ>$
ÒJè
,OCT

,-80℃
ìà

ƒªìàd„

μm,-80℃íµX¯;‚n$!”£$C`,Ì~


XÌ~d„¯

15 
äò

ßíq}Šý
 
,™´ìàd„W
ìZ$3Ö

ðSþE
15min,60%
Eg˜9·d
„

äò

ß>ßí
15min,60%
Eg˜·:Zn
ß>

MäJ©·
2min,
+ASfßl’p
1min,
MäJ©·ËÞ
5min,
Šäµ„

Vî}SŠýq
·4961·
Y 
ùÉ

cdúef
db/db
:gRP×hiÖjkl’·_¡mœno‰Š
}eNqï¯
ImageProPlus
rø©s¡¢

16 
c£Ò¸_¶º
 
3D5™´Ò¸
,10%
$
!ӣC`

Ì~pŽ


(5μm)。ƒªÒ~¬
J
,TBST
·‹

}
,3% H2O2’[15min,æ,^
f
,TBST
·‹

}

ƒ2
CD68(1∶400)
î•
F4/80
(1∶200)


Þ
4℃
ìZè



ð½Þ
30
min,TBST
·‹

}

ƒ2,
,37℃
’[
30min,
DAB
VííVí
(1∶150),
|}J©·

+ASfß

ƒªÀ^ÒJ

”7Ì¡

$!Ž’µ„

}{Vî
}SŠýqï¯
ImageProPlus
rø©s¡¢á 

17 
nOÅ_`†
PCR(quantitativerealtime
PCR) 
,Ò¸W>—$3Ö½ù
15mL
vSK
$

2ù`†
TRIzol
ÿÞêìf

UƒÆ…fïÒ
¸~¡/Ýÿ


100μL.Œ,+6ƒ40s,=
Þ
2min
ï‚MÌ¡â
;4℃,13000r·min-1
vS
15min,¯
î†É>´:S”3.fL>óÉùD
œ
EP
K$

|CK$2ùÉóEœEg˜

ŽÜ
î

ð=Þ
10min
ï
RNA
°I
;4℃,13000r·
min-1
vS
10min,
Í:fœ


75%

(DEPC
Jֈ
)1mL
·:Eg˜q_}
4℃,13000r·
min-1
vS
5min;
½ùž×g‡3$M̏’


30μLœRNasefreeJÎÝ;º`RNA™^,é–ò
íäúû„lmÿ‹nÅ_`†
PCR。
¢¨ª«
w
Invitrogen
BCDEê«

¢¨ÆO„Ÿ
2。
Ÿ
2 
nOÅ_`†
PCR
¢¨ÆO
Table2 ListofprimersusedforquantitativerealtimePCR
•› ‘좨
(5′3′)
õ좨
(5′3′) PCR
w:
/bp
Ucp2 ATGGTTGGTTTCAAGGCCACA CGGTATCCAGAGGGAAAGTGAT 109
TNFα CAGGCGGTGCCTATGTCTC CGATCACCCCGAAGTTCAGTAG 89
Ccl2 TTAAAAACCTGGATCGGAACCAA GCATTAGCTTCAGATTTACGGGT 121
F4/80 CTGCACCTGTAAACGAGGCTT GCAGACTGAGTTAGGACCACAA 127
CD68 TGTCTGATCTTGCTAGGACCG GAGAGTAACGGCCTTTTTGTGA 75
Mrc1 CTCTGTTCAGCTATTGGACGC TGGCACTCCCAAACATAATTTGA 190
Arg1 CTCCAAGCCAAAGTCCTTAGAG AGGAGCTGTCATTAGGGACATC 184
18 
=ò©s‘}
 
ºBs†=òƟÄÓ
珋x±s,w¯GraphPadPrism60rø‹n©s¡¢,
¶oúûw¯
OnewayANOVA
¡¢#
Dunnett

o
,P<005
ŠÓEB©sd€

2 
á 
21 
™Ò¸ôÊý
 
‘ƒÏ–Ò
db/m
:g
™´ôу

íDòÒ

…Fr
。db/db
:g™
Ò¸óEEƒ@w

íD–(

…Fˆ†

ŸDä‘
ΈV¹

2ÄÚÒ:g™´R÷NI

CÄcd
úÿ

íD…FÆBV¹ef

q…=¡Vä‘Î

óEV¹*:

„q
1。
Adb/m
:g
;Bdb/db
:g
;Cdb/db+TSF
:g

q
1 
xÒ:g™´+Š
Fig1 Morphologicalstudyofthelivers
22 
cdúÏ
db/db
:gó#™œØÙ
 db/
db
:gˆ
db/m
:gó@2V¹

JKC,
12

ÿ

Ö
db/db
Ò⟈

cdú?V¹*F
db/db
:
gó@2#™´…†

„q
2。
23 
cdúÏ
db/db
:gtR™´R…°Eœ
ØÙ
 
Ö
db/m
:gâŸ
,db/db
:gtœ$
TC
#
TG
á†V¹f­

Ÿ¡:gó8ÖÝR÷P×E
ƒ

CÄcdúÿ?V¹T«
db/db
:gtœ
TC
#
TG


Ù+

äò

ßíVÄ
db/m
:g™l
’\Ç=R÷ƒ

™l’@$ýQ

Í
db/db
:g™
´Ò¸¡$w†R÷ƒ#ø8

R÷N!“^I

äò

Ú!ÏíDEV¹@2

CÄcdú‚œ
:gR…°EV¹ST

ø8*F

„q
3。
24 
cdúÏ
db/db
:g™´Ò¸jkl’·_
œØÙ
 
nOÅ_`†
PCR
á VÄ

֑ƒ
db/

:gŸˆ
,db/db
:g™´Ò¸jkl’ëj¨
•›
CD68
#
F4/80
V¹f»

CÄcdúÿŸ 
ÆBV¹ST

c£Ò¸_á ¦…vncdú
?V¹T«
CD68
#
F4/80
œŸ 

„q
4。
25 
cdúÏ
db/db
:göíR÷Ò¸jkl’
·5961·
2016
y

z À
41
ÁÀ

}
Vol41,No.9 May,2016
   
Ö
db/m
:gâŸ
P<0001;
Ö
db/db
:gâŸ
#P<001,##P<0001。
q
2 
xÒ:góN_֙
Fig2 Changesinbodyweightgainandtheliverweight
Ö
db/m
:gâŸ
P<005,P<0001;
Ö
db/db
:gâŸ
#P<005(
q

¦
)。
q
3 
xÒ:gtœ$
TC,TG
Jþ™´äò

ßí
(×400)
Fig3 QuantificationofTCandTGinserumandhepaticOilRedOanalysis(×400)
¸_¡mœØÙ
 
֙´Ò¸$jkl’·_OP
â¦
,db/db
:göíR÷Ò¸
(whiteadiposetissue,
WAT)CD68
#
F4/80
•›
mRNA
JþV¹‰ê
db/m
:g

Ícdú?V¹Mˆ
CD68
#
F4/80
mRNA
œJþ

Ù+

Ö
db/m
:gâŸ
,db/db
:g
öíR÷Ò¸jkl’
M1
·_ëj¨¢£Fä›
¶α(tumornecrosisfactorα,TNFα)mRNAJþV
¹­‰

CÄcdúÿ?V¹T«‚Ÿ 
;M2

_ëj¨Š‡c

mYó
1(mannosereceptorC
type1,Mrc1)
#Õ¡‘š
(arginase,Arg1)
¦…V¹


vcdú’õÿqbMˆ‚
mRNA


Ö
Ù¦O

è_›¶
(chemokineligand2,Ccl2)
#Ýc
>Ãö
2(uncouplingprotein2,Ucp2)mRNA
Jþ†
ˆ
db/m
:gV¹f»

cdú’õÿV¹Mˆ‚
Ÿ 

„q
5。
3 
s
C57BLKS/Jdb/db
:gû
Leptin
Yó•›G¾
˜þœMmm

mš€Öc¦q:g

‚¼BtR

tcEƒ

ó@2ɟÝ

NB™´R÷…NÖ
Ý

û/œR÷™ƒ¨xm…[

£õnoʯ
db/db
:g‡ÓnoÏc䉊cdú¤»ÁRP
×hi$œ‡¯âãfˆ

NAFLD
mqfˆˆÓf-

w
Day
#
James
¤
1998
y2֜

}]–

HûååˆÓDXœ
mqfˆ
[5]。
¼0wꚀ

c¦qɘþ„¸S
…,¢ÏRP×Eƒ

~vR÷‘ÖŠäLþ­‰

·6961·
Y 
ùÉ

cdúef
db/db
:gRP×hiÖjkl’·_¡mœno‰Š
  
q
4 
xÒ:g™´Ò¸$
CD68,F4/80
Ÿ N_
(×400)
Fig4 RTPCRandimmunohistologicalstainingofhepaticCD68andF4/80(×400)
Ö
db/m
:gâŸ
P<005,P<001,P<0001;
Ö
db/db
:gâŸ
#P<005,##P<001,ns
=V¹!E

q
5 
xÒ:göíR÷Ò¸jkl’ëj¨Ÿ N_
Fig5 ThemRNAlevelsofmarkersofmacrophageactivation
E·°E¤™´ÉÒ¸e«™R÷N

À}]–
wêfó8-_þE¯»˜þœ-_ö™

΅Ö
ÝRï!Öÿ§›¶½½þï™l’Y¥

ãyäuäuZœ•ãëW™´jkl’r
˜œc£õö†‡û
NAFLD
mqfˆœ•ÌÍÏ
Wâ_œ»Á‡¯
[68]。
jkl’Ó[ÆE…!
ˆwœl’

‚ä>êÈ÷l’q¡_Ó«ºœR
pl’‹ù+t

Ìÿ‹ùxÒ¸ÿ¡_Ójk


‹™´$œ
Kufer


¤¥¦œ©}q}#
֙OPSjkl’+B¥¦œ™·¬­

mEx
Mœ©¨Ä—

™´ûBó_œc£´µ

R
÷Ò¸-©œZ±l’›¶‹è_›¶

¢£Fä
›¶¢+ϙ´Ò¸œ8MÄ-©ØÙ

‹—˜Ò
¸-©·!-

‹Í˜þR÷™œm©mŒ

Ù+

R…Eƒ°E¤™´Ò¸†+֙
Kufer
l’™·
W͢ϩKœÿ§õö

[ôOœá ,+™
·™7Þl’‹Í¢mš›_œm©
[9]。
w†‰ŠŸ¡

jkl’ÏR÷™ÿ§õöB
·7961·
2016
y

z À
41
ÁÀ

}
Vol41,No.9 May,2016
Ïև¯

~Mÿ#,ÿ‡¯

-©…œá û
w‚·_§mª`œ
[10]。
öíR÷Ò¸¡¤œ
TNFα,IL6Él’›¶jkl’œ·_?˜þ
¡Vœ„¸S…,֚€qBœ™´¥¦
[1112]。
õ‰Šá VÄ

cdúJKC,
12
ÿ?V¹T
«tœŠäLþ

u+C˜Jþq*™´R÷N
“^

Ù+

cdúV¹Mˆ™´Ò¸#öíR÷Ò
¸$
CD68
Ö
F4/80
œŸ 

2ÄcdúÏR÷™
:gó8jkl’œ™·B[`œMˆ‡¯

‹[
:¡¢mÝcdú?MˆöíR÷Ò¸
M1
·_ë

TNFαmRNAœŸ ,Í M2m·_ëj¨
Mrc1
#
Arg1
Ø=V¹T«

gº?—ûR÷Ò
¸8MÄeNœ[±íª!fˆ

ã}B‰Šm
Ý

jkl’¤
NAFLD
œÿ§mmßé#ÿ}w†
$!¨l’

y@l’œRÒBÏ]dœ>ô

õ‰
ŠÖÙ䉊¢Ÿ¡âjkl’œ·_¤
NAFLD
m©mŒ“ÏÏ_œ‡¯
[1314]。
vjkl’
œ¡mŠ’w<±¡¶Öfˆª`

ååq¥$¡
œ@

Ž<ëdœû

Ö
db/m
:gâŸ
,db/db
:
göíR÷Ò¸$
Ucp2
#
Ccl2
Ÿ ­‰

cdú
¦…?ÂMˆ‚Ÿ Jþ

Ÿ¡cdúefRP×
hi?—Ö‚»ÁR…-_#Mˆÿ!l’RÒ


B‰ŠŸ¡

ÿ§¥¦û˜þ
NAFLD
m©‹
ŒœÃz¾G›S

q?Â@™´R÷‘lƒÃ
ö
CD36
‹ÍïMô©$w†R÷‘‹ù™´ª
«ZœR…W͎‹
NAFLD
œm©mŒ
[15]。
w
Ù?„

ÿ§MÄs‚û™´#öíR÷Ò¸$w
†jkl’œRÒÂÖâ
NAFLD
œ‹Œ

bf

c
dú?ÂV¹ef
db/db
:gRP×Eƒ™R÷
N

‚fˆ?—ÖMˆjkl’
M1
m·_

ef™
´#R÷Ò¸8MÄÿ§ÞÃBã


uv=w

[1] LoombaR,SanyalAJ.TheglobalNAFLDepidemic[J].Nat
RevGastroenterolHepatol,2013,10(11):686.
[2] GordonS,MartinezFO.Alternativeactivationofmacrophages:
mechanismandfunctions[J].Immunity,2010,32(5):593.
[3] 


!wY

$¹+

É

cdúÏMm!

mc¦qx
mwgRPׁ™´RNœØÙ
[J].
$š$A,-.

2010,25(11):1778.
[4] LiP,ChenY,LiuJ,etal.Eficacyandsafetyoftangshenfor
mulaonpatientswithtype2diabetickidneydisease:amulti
centerdoubleblindedrandomizedplacebocontroledtrial[J].
PLoSONE,2015,10(5):e0126027.
[5] DayCP,JamesOF.Steatohepatitis:ataleoftwo"hits"?
[J].Gastroenterology,1998,114(4):842.
[6] YaoJ,ZhouCS,MaX,etal,FXRagonistGW4064aleviates
endotoxininducedhepaticinflammationbyrepressingmacrophage
activation[J].WorldJGastroenterol,2014,20(39):14430.
[7] WehrA,BaeckC,UlmerF,etal.Pharmacologicalinhibitionof
thechemokineCXCL16diminisheslivermacrophageinfiltration
andsteatohepatitisinchronichepaticinjury[J].PLoSONE,
2014,9(11):e112327.
[8] Lastra,G,ManriqueC,JiaG,etal.TheVASProadtoNAFLD:a
macrophagedetour[J].Diabetes,2015,64(8):2711.
[9] BrowningJD,HortonJD.Molecularmediatorsofhepaticsteato
sisandliverinjury[J].JClinInvest,2004,114(2):147.
[10] DiehlAM.NonalcoholicsteatosisandsteatohepatitisIV.Nonal
coholicfatyliverdiseaseabnormalitiesinmacrophagefunction
andcytokines[J].Am JPhysiolGastrointestLiverPhysiol,
2002,282(1):G1.
[11] KernPA,RanganathanS,LiC,etal.Adiposetissuetumor
necrosisfactorandinterleukin6expressioninhumanobesityand
insulinresistance[J].AmJPhysiolEndocrinolMetab,2001,
280(5):E745.
[12] CanceloR,TordjmanJ,PoitouC,etal.Increasedinfiltrationof
macrophagesinomentaladiposetissueisassociatedwithmarked
hepaticlesionsinmorbidhumanobesity[J].Diabetes,2006,55
(6):1554.
[13] GaddVL,SkoienR,PowelEE,etal.Theportalinflammatory
infiltrateandductularreactioninhumannonalcoholicfatyliver
disease[J].Hepatology,2014,59(4):1393.
[14] KitadeH,SawamotoK,NagashimadaM,etal.CCR5playsa
criticalroleinobesityinducedadiposetissueinflammationand
insulinresistancebyregulatingbothmacrophagerecruitmentand
M1/M2status[J].Diabetes,2012,61(7):1680.
[15] WangC,HuL,ZhaoL,etal.Inflammatorystressincreaseshe
paticCD36translationaleficiencyviaactivationofthemTOR
signalingpathway[J].PLoSONE,2014,9(7):e103071.

xy-0
 
”•–

·8961·